Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ITOS Stock Forecast 2025-2026
$10.15
Current Price
$448.68M
Market Cap
Buy 0
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to ITOS Price Targets
+8.4%
To High Target of $11.00
-1.0%
To Median Target of $10.05
-1.5%
To Low Target of $10.00
ITOS Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+22.3%
1 Year Change
+32.2%
Year-to-Date Change
-42.4%
From 52W High of $17.63
+111.5%
From 52W Low of $4.80
📊 TOP ANALYST CALLS
Did ITOS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if iTeos is one of their latest high-conviction picks.
Latest ITOS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ITOS has a neutral consensus with a median price target of $10.05 (ranging from $10.00 to $11.00). The overall analyst rating is Buy (6.0/10). Currently trading at $10.15, the median forecast implies a -1.0% downside. This outlook is supported by 0 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Eva Fortea Verdejo at Wells Fargo, projecting a 8.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ITOS Analyst Ratings
0
Buy
4
Hold
0
Sell
ITOS Price Target Range
Low
$10.00
Average
$10.05
High
$11.00
Current: $10.15
Latest ITOS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ITOS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 7, 2025 | Wells Fargo | Eva Fortea Verdejo | Equal-Weight | Maintains | $11.00 |
| May 28, 2025 | Wedbush | David Nierengarten | Neutral | Downgrade | $12.00 |
| May 28, 2025 | Wells Fargo | Eva Fortea Verdejo | Equal-Weight | Downgrade | $12.00 |
| May 14, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $12.00 |
| May 14, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $13.00 |
| May 14, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Neutral | Downgrade | $N/A |
| May 14, 2025 | Leerink Partners | Daina Graybosch | Market Perform | Downgrade | $9.00 |
| May 13, 2025 | JP Morgan | Brian Cheng | Neutral | Downgrade | $8.00 |
| Apr 29, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $16.00 |
| Mar 6, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $17.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $46.00 |
| Mar 6, 2025 | JP Morgan | Brian Cheng | Overweight | Maintains | $15.00 |
| Jan 16, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $21.00 |
| Dec 19, 2024 | Wells Fargo | Overweight | Maintains | $N/A | |
| Dec 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $21.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $46.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $46.00 |
| Aug 13, 2024 | Wells Fargo | Eva Fortea Verdejo | Overweight | Initiates | $31.00 |
| Aug 12, 2024 | JP Morgan | Brian Cheng | Overweight | Maintains | $24.00 |
| May 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $46.00 |
Iteos Therapeutics Inc. (ITOS) Competitors
The following stocks are similar to iTeos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Iteos Therapeutics Inc. (ITOS) Financial Data
Iteos Therapeutics Inc. has a market capitalization of $448.68M with a P/E ratio of 40.8x. The company generates $35.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -440.9% and return on equity of -35.0%.
Valuation Metrics
Market Cap
$448.68M
Enterprise Value
$-61,617,212
P/E Ratio
40.8x
PEG Ratio
0.0x
Price/Sales
12.8x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-440.9%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+114.9%
Current Ratio
7.5x
Debt/Equity
1.0x
ROE
-35.0%
ROA
-18.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Iteos Therapeutics Inc. (ITOS) Business Model
About Iteos Therapeutics Inc.
What They Do
Biotechnology company focused on oncology therapeutics.
Business Model
Iteos Therapeutics generates revenue through the discovery and development of innovative immuno-oncology therapies. By creating novel drug candidates that enhance the immune system's ability to combat cancer, the company collaborates with major pharmaceutical partners to leverage resources and expertise, thereby increasing its market reach and potential profitability.
Additional Information
The company is committed to advancing cancer treatment paradigms and is situated in a competitive landscape within the biotechnology sector. Iteos Therapeutics aims to push the boundaries of cancer therapy and is focused on delivering transformative solutions for patients globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
173
CEO
Dr. Michel Detheux Ph.D.
Country
United States
IPO Year
2020
Website
www.iteostherapeutics.comIteos Therapeutics Inc. (ITOS) Latest News & Analysis
Latest News
Quick Summary
Kahn Swick & Foti, LLC is investigating iTeos Therapeutics' proposed sale to Concentra Biosciences, offering $10.047 per share plus contingent value rights, to assess if the deal is adequate.
Why It Matters
The investigation into iTeos Therapeutics' sale may affect share prices, as concerns about undervaluation could lead to renegotiation or investor action, impacting market sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of Shareholders
3 months ago
Quick Summary
Halper Sadeh LLC is investigating iTeos Therapeutics (NASDAQ: ITOS) for potential securities law violations related to its sale to Concentra Biosciences for $10.047 per share plus contingent value rights.
Why It Matters
The investigation into iTeos Therapeutics' sale to Concentra raises concerns about potential shareholder rights violations, which could affect stock value and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
iTeos Therapeutics will be acquired by Concentra Biosciences for $10.047 per share in cash, plus contingent value rights related to excess cash and future product sales.
Why It Matters
The merger agreement offers iTeos shareholders a cash payout and additional value through contingent rights, affecting stock valuation and potential returns on investment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)
4 months ago
Quick Summary
Monteverde & Associates is investigating iTeos Therapeutics' sale to Concentra Biosciences for $10.047 per share, plus contingent value rights based on future cash and product proceeds.
Why It Matters
The investigation into iTeos Therapeutics' sale could indicate potential shareholder disputes or class action risks, impacting stock price and investor confidence in the deal's fairness.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.
4 months ago
Quick Summary
Rowley Law PLLC is investigating iTeos Therapeutics (NASDAQ: ITOS) for potential securities violations related to its acquisition by Concentra Biosciences, offering $10.047 per share plus contingent value rights.
Why It Matters
The investigation into iTeos Therapeutics' acquisition could signal potential legal troubles, impacting share value and investor confidence in the deal's integrity.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the fairness of Concentra Biosciences' proposed acquisition of iTeos Therapeutics for $10.047 per share, plus contingent value rights for shareholders.
Why It Matters
The investigation into iTeos' sale may signal potential undervaluation or legal issues, affecting share price and investor confidence in the deal's fairness.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ITOS Stock
What is Iteos Therapeutics Inc.'s (ITOS) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Iteos Therapeutics Inc. (ITOS) has a median price target of $10.05. The highest price target is $11.00 and the lowest is $10.00.
Is ITOS stock a good investment in 2026?
According to current analyst ratings, ITOS has 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ITOS stock?
Wall Street analysts predict ITOS stock could reach $10.05 in the next 12 months. This represents a -1.0% decrease from the current price of $10.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iteos Therapeutics Inc.'s business model?
Iteos Therapeutics generates revenue through the discovery and development of innovative immuno-oncology therapies. By creating novel drug candidates that enhance the immune system's ability to combat cancer, the company collaborates with major pharmaceutical partners to leverage resources and expertise, thereby increasing its market reach and potential profitability.
What is the highest forecasted price for ITOS Iteos Therapeutics Inc.?
The highest price target for ITOS is $11.00 from Eva Fortea Verdejo at Wells Fargo, which represents a 8.4% increase from the current price of $10.15.
What is the lowest forecasted price for ITOS Iteos Therapeutics Inc.?
The lowest price target for ITOS is $10.00 from at , which represents a -1.5% decrease from the current price of $10.15.
What is the overall ITOS consensus from analysts for Iteos Therapeutics Inc.?
The overall analyst consensus for ITOS is neutral. Out of 8 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $10.05.
How accurate are ITOS stock price projections?
Stock price projections, including those for Iteos Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 10, 2025 9:12 AM UTC